Back Bay Life Science Report
By Jonathan P. Gertler and Peter Bak
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by Jonathan P. Gertler and Peter Bak
Category: Medicine
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 0
Reviews: 0
Episodes: 35
Description
Back Bay Life Science Advisors brings you expert insights from our strategic advisors and investment bankers on biopharma, medtech, and medical device development, trends, and growth areas. On this podcast, you’ll hear from our experts in life science development, commercialization, and investment banking, scientific investigators, biotech and medtech executives, physicians, and strategists who excel at guiding global life sciences companies and their investors through complex decisions. Join us for insights generated from in-depth scientific, strategic, and financial analysis at the intersection of science and business.
| Episode | Date |
|---|---|
|
Evolving Oncology: The Expanding Landscape of Targeted Therapies and Investment
|
Apr 15, 2026 |
|
ADC Revolution in Ovarian Cancer: Current Developments and Future Outlook
|
Mar 05, 2026 |
|
2025 Drug Approval Review
|
Feb 09, 2026 |
|
A Capital Markets Outlook for 2025: 2024, A Year in Review
|
Feb 07, 2025 |
|
The Optimism of Bispecific Antibodies
|
Nov 08, 2024 |
|
Dynamics in Healthcare Focused Markets
|
Sep 30, 2024 |
|
From NASH to MASH: Current Market Dynamics in Hepatology
|
Sep 16, 2024 |
|
Key Considerations for a US Healthcare IPO
|
May 22, 2024 |
|
Drug Development in Obesity
|
Apr 30, 2024 |
|
The Current Dynamics in Capital Markets
|
Apr 15, 2024 |
|
Vaccine Developments 2024: A Podcast Discussion on Latest Vaccine Technology and Ongoing Clinical Developments
|
Mar 18, 2024 |
|
Trends and Investment Activity in Radiopharmaceuticals and Psychedelics
|
Feb 14, 2024 |
|
Vertex’s Exa-cel to Biogen and Sage’s Zurzuvae: Notable Product Approvals of 2023
|
Jan 03, 2024 |
|
Monthly Roundup of News from Healthcare Development
|
Nov 07, 2023 |
|
The Current and Future Landscape of Healthcare IPO Markets
|
Oct 27, 2023 |
|
The Heart of the Matter: Behind the Renewed Interest in Cardiovascular Disease
|
Oct 12, 2023 |
|
The Transactional Landscape Of ADCs: The Powerhouse of Antibody Drug Conjugates
|
Aug 29, 2023 |
|
Investing in Health Tech & Digital Medicine: Expert Talk with Mikaela Odlander & Edward Kliphuis
|
Apr 14, 2023 |
|
Contingencies for Biopharma, Medtech Deal Planning in a Down Market
|
Feb 09, 2023 |
|
Gene Editing to Cross-Species Transplantation: The Most Compelling Healthcare Stories of 2022
|
Jan 24, 2023 |
|
Preparing BioPharma and Medtech Companies for Public Listing - Back Bay Life Science Advisors and Nasdaq Nordic
|
Sep 19, 2022 |
|
The Promising Field of Targeted Protein Degraders (TPDs)
|
Jul 30, 2022 |
|
Early Market Access and Pricing with Pete Bak, Christian Thieniel and Brendan Wang
|
Jul 06, 2022 |
|
Living Medicines – Current and Future Uses of Car T Cells with Peter Bak, PhD and Mike Bogetofte Barnkob, MD, PhD
|
May 19, 2022 |
|
The Evolving Regulatory Framework for Novel Medicines in the EU
|
Apr 25, 2022 |
|
The Commercial Potential of Optogenetic Therapies
|
Mar 15, 2022 |
|
The Latest on Antibiotic Development, Back Bay Life Science Advisors with Antabio
|
Jan 19, 2022 |
|
Best Practices for Successful Sell-Side Licensing, Partnering and M&A
|
Jan 07, 2022 |
|
Cell and Gene Therapy Investment Trends
|
Nov 22, 2021 |
|
MedTech Investing with Paul LaViolette of SV Health Investors and Jonathan P. Gertler, MD, Back Bay Life Science Advisors and BioVentures Medtech Funds
|
Oct 13, 2021 |
|
Remote Patient Monitoring
|
Aug 05, 2021 |
|
New Drug Pricing and Market Access
|
Jun 30, 2021 |
|
The Question of Investment in Antimicrobials
|
Jun 11, 2021 |
|
Life Science SPACs: A Forward Look at this Evolving Asset Class
|
Jun 03, 2021 |
|
Gene Therapies: What’s to Come as The Industry Moves Forward
|
Jun 02, 2021 |